RxDoctor Payments Data

Christopher Huser, MD

Pain Medicine · Englewood, CONPI 1932206604

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 614 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.

$14,017in general payments, 2019–2025

Across 614 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • AbbVie$2K
  • Collegium Pharmaceutical, Inc.$941
  • Amgen$522
  • Scilex Pharmaceuticals Inc.$479
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$443
  • plus $7K from 53 others

What the payments were for

  • Food & beverage$14,013100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific46$2,663
AbbVie(2 entities)121$2,053
Collegium Pharmaceutical, Inc.60$941
Amgen(2 entities)21$522
Scilex Pharmaceuticals Inc.30$479
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$443
Abbott10$435
Lilly USA, LLC25$399
Lundbeck LLC18$365
Zyla Life Sciences, Inc.59$349
MML US, Inc.4$349
Medtronic6$326
Stimwave Technologies Incorporated5$304
Pfizer17$298
Vertos Medical, Inc.2$297
Averitas Pharma Inc.13$288
Saluda Medical Americas, Inc.6$285
GRT US Holding, Inc.12$214
Nalu Medical, Inc.2$205
Nevro Corp.8$205
Painteq LLC2$187
Biodelivery Sciences International, Inc.10$169
Stryker1$163
Novartis10$157
Relievant Medsystems, Inc.2$157
Sentynl Therapeutics, Inc.13$145
SPR Therapeutics, Inc4$121
IBSA Pharma Inc.6$115
Teva Pharmaceuticals USA, Inc.7$113
Biohaven Pharmaceutical Holding Company Ltd.5$98
Biohaven Pharmaceuticals, Inc.5$96
Almatica Pharma LLC4$95
Pacira Therapeutics, Inc.5$85
Bioventus LLC4$76
Takeda Pharmaceuticals U.S.A., Inc.5$74
Radius Health, Inc.4$74
Daiichi Sankyo Inc.4$69
Kaleo, Inc.3$60
Zimmer Biomet3$54
MDD US Operations, LLC4$50
Vertex3$48
Spinal Simplicity, LLC2$47
Merck2$35
Tonix Medicines, Inc.1$31
Convatec Inc.1$30
Redhill Biopharma Inc.2$28
Upsher-smith Laboratories LLC2$25
Si-bone, Inc.1$23
Idorsia Pharmaceuticals US Inc1$22
Shionogi Inc1$19
Assertio Therapeutics, Inc.1$18
Azurity Pharmaceuticals, Inc.1$18
Promius Pharma LLC1$17
Curonix LLC1$15
Eisai Inc.1$13
Kowa Pharmaceuticals America, Inc.1$13
Impel Pharmaceuticals Inc.1$13
Supernus Pharmaceuticals, Inc.1$13
Johnson & Johnson1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,017 in reported general payments places this provider in the 85th percentile of 96 pain medicine providers in Colorado.

See all pain medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$297,768
Medicare patients
661
Services billed
2,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant15$16,563
BelbucaBuprenorphine Hcl21$13,117
Buprenorphine29$9,795
MovantikNaloxegol Oxalate14$5,438
Gabapentin139$1,985
Oxycodone Hcl89$1,748
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen43$1,721
Pregabalin77$1,356
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen47$1,259
Morphine Sulfate ErMorphine Sulfate40$942
Lidocaine14$935
Cyclobenzaprine Hcl41$777
Duloxetine Hcl40$601
Tizanidine Hcl49$544
Celecoxib30$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$2,053$16,56315 claims
Collegium Pharmaceutical, Inc.Belbuca$941$13,11721 claims
Redhill Biopharma Inc.Movantik$28$5,43814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 96 pain medicine providers in Colorado.

Other pain medicine in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →